Topic: Parkinson's disease
The week’s biotech discoveries included compounds in broccoli and ragweed with potential disease-fighting properties.
Abbott pledged to provide its neuromodulation tech for the public-private NIH research effort.
Pfizer spun off some of its CNS assets into Cerevel Therapeutics in 2018.
The Michael J. Fox Foundation and 23andMe are launching a network aimed at combining the patient voice and genetic data from Parkinson’s patients.
Roland Bürli, Ph.D., jois Cerevance as the CNS-focused biotech looks to advance a suite of treatments for Parkinson’s and Alzheimer’s disease.
The company says its new name aligns with its focus on developing regenerative therapies for diseases such as Alzheimer’s and Parkinson’s.
With $225 million from TPG Capital and Vida Ventures and $10 million from its founders and board members, AskBio will ramp up clinical trials and manufacturing.
The funding will support research intended to improve the chances that Inflazome will succeed in the clinic.
Based on phase 2 data, a Georgetown University team showed that Tasigna reduces toxic protein clumps and restores dopamine metabolism in Parkinson's.
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.